Stem Cell Clinic

LabRoots Announces Speakers to Present Cutting-Edge Research Findings at its 4th Annual Cell Biology Virtual Conference – PR Web

Cell Biology Virtual Event, September 23, 2020

YORBA LINDA, Calif. (PRWEB) September 17, 2020

LabRoots, the leading scientific social networking website offering premier, interactive virtual events and webinars, will be hosting its Cell Biology Virtual Event, scheduled on September 23, 2020. This day-long forum marks the fourth annual event that will attract innovative researchers, top scientists, biologists, and leading academia and industry from across the globe.

Emphasizing the principals and fundamentals of biology, the one-day program features four sessions encompassing Organelle Dynamics, Cell Biology of Cancer, Extra Cellular Matrices, and Exosomes convening global leaders to present their latest progress in cell research. Discussions on transformative new technologies and applications in the field will be unveiled via over 15 scientific presentations on topics such as the role of Nox-derived Reactive Oxygen Species in Axonal Growth and Guidance, the journey into discovery oncology at the crossroad of cell biology, Extracellular Matrix in Renal Development and Cancer, GeoMx Digital Spatial Profiling read-out for Next-Generation Sequencers with the Cancer Transcriptome Atlas (CTA), Extracellular Vesicles and Chronic Kidney Disease, and Beyond the Culture Flask: How Membrane- and Microfluidic-based Platforms can create more Physiologically Relevant Tissue Culture Systems, naming a few.

This years first keynote address will be given by internationally recognized Muller Fabbri, MD, PhD, Associate Professor, Co-Leader Cancer Biology Program, University of Hawaii Cancer Center, explaining how MicroRNAs in Extracellular Vesicles orchestrate the biology of the Tumor Microenvironment. The programs second keynote will be delivered by Steve Caplan, PhD, Professor and Vice Chair for Administration, Dept. of Biochemistry and Molecular Biology, Director, UNMC Advanced Microscopy Core Facility on sorting out the mechanisms of endocytic recycling. Following, Benedetta Bussolati, Associate Professor of Nephrology, University of Torino, President of the Italian Society for Extracellular Vesicles, and internationally known for her studies of stem cell biology and regenerative medicine, will explore Extracellular vesicles in Regenerative Medicine during her keynote presentation. Lastly, the final keynote talk presented by Kenneth W. Witwer, PhD, Associate Professor, Molecular and Comparative Pathobiology, John Hopkins University of School of Medicine will explore starting at the source: tissue extracellular vesicles and Alzheimers disease.

This Cell Biology event produced by Labroots includes different tracks on the most exciting approaches to understand Cell Biology, ranging from exosome/extracellular vesicles to proteomics and cancer biology, said Dr. Laura Perin, Assistant Professor at the Keck School of Medicine, University of Southern California, and Planning Committee Member. The Committee is grateful to the high caliber leaders and experts that will share insights and novel research which are fundamental in advancing the field of medicine bringing innovative avenues for the discovery of new treatments for our patient populations.

Cell Biology 2020 is committed to continuing our unique tradition of bringing the scientific community together providing the discovery, innovation, and medical advances that drive biomedical research forward, said Greg Cruikshank, Chief Executive Officer of LabRoots. For the 4th consecutive year, were delighted to showcase some of the brightest minds in cell science on the agenda, while offering cutting-edge educational content for our attendees on a global front.

The online event produced on LabRoots signature platform allows participants to learn and connect seamlessly across all desktop and mobile devices. Featuring up-to-date emerging findings from the field in the auditorium, poster and exhibit halls, and a networking lounge to foster collaborations, Cell Biology 2020 delivers an all-inclusive interactive environment. By attending this event, you can earn 1 Continuing Education credit per presentation for a maximum of 30 credits.

To register for the event and for more information, click here. Participants can follow the conversation online by using #LRcellbio.

About LabRoots LabRoots is the leading scientific social networking website, and primary source for scientific trending news and premier educational virtual events and webinars and more. Contributing to the advancement of science through content sharing capabilities, LabRoots is a powerful advocate in amplifying global networks and communities. Founded in 2008, LabRoots emphasizes digital innovation in scientific collaboration and learning. Offering more than articles and webcasts that go beyond the mundane and explore the latest discoveries in the world of science, LabRoots users can stay atop their field by gaining continuing education credits from a wide range of topics through their participation in the webinars and virtual events.

Share article on social media or email:

Excerpt from:
LabRoots Announces Speakers to Present Cutting-Edge Research Findings at its 4th Annual Cell Biology Virtual Conference - PR Web

VA researchers study effects of smoking on therapeutic stem cells – VAntage Point Blog

Many in the research community believe there is huge potential for stem cell therapy to treat a broad range of diseases. Stem cells, special human cells that can develop into many different cell types, essentially serve as a repair system for the body.

Currently, more than 5,000 clinical trials worldwide are based on therapeutic stem cells, including some at VA hospitals for illnesses ranging from cardiovascular disease to cancer.

But gaps remain in the transition of stem cell application from the research stage to patients.

One of these gaps is how a patients lifestyle choices and underlying health conditions may negatively affect stem cell therapy, says Dr. Ngan Huang, a biomedical engineer at the VA Palo Alto Health Care System in California. Given the prevalence of cigarette use and rise of electronic cigarettes, we believe this subject is an important aspect of stem cell application that remains unexplored. Not much is known about nicotine and its direct effect on therapeutic stem cells.

Huang and Dr. Alex Chan, a postdoctoral research fellow at VA Palo Alto, are studying the effects of nicotine, a highly addictive tobacco stimulant normally inhaled with cigarettes, on therapeutic stem cells. The two co-authored a review article on the effects of nicotine on stem cell therapy that appeared online earlier this year in the journal Regenerative Medicine.

There are two arms to their study. In one, Huang and Chan are injecting cells into mice that have been exposed to nicotine, as well as those that havent, with the intention of treating peripheral artery disease, which obstructs blood vessels in the arms and legs. In the other arm, the researchers will compare stem cells in smokers and non-smokers. They will see if the groups differ at producing cells that are effective at making new blood vessels.

Veterans and service members are more likely to use tobacco products than civilians, according to the U.S. Centers for Disease Control and Prevention (CDC). CDC statistics show that about 30% of Veterans used some form of a tobacco from 2010 to 2015. Tobacco use was higher among Veterans than non-Veterans for males and females across all age groups, except men ages 50 and older.

Huang and Chan are hoping to bring more awareness about the effects of smoking on stem cells to the Veteran community, as well as other types of nicotine exposure that may impact the effectiveness of stem cell therapy, such as electronic cigarettes. E-cigarettes, also known as vapes, are battery-operated devices that people use to inhale an aerosol, which typically contains nicotine, flavorings, and other chemicals that are known to harm ones respiratory system.

The effects of lifestyle and co-occurring health conditions on stem cells have been largely neglected, Chan explains. Preclinical studies of stem cell therapies have mainly been conducted in healthy animal models. This does not reflect the settings in the clinics where patients requiring stem cell therapy may have underlying diseases, such as diabetes, high blood pressure, and lifestyle choices like smoking and diet.

The overall results from the study, Huang notes, may prompt researchers to take nicotine or tobacco exposure into consideration in clinical trials. As more trials take place for stem cell therapies in many applications, she says, the field will trend toward more effective therapies.

But with many unknowns, it will be years before stem cells therapies become the gold standard treatment for certain diseases, she says.

Click here to read the full story.

Click here to learn more about VA research.

Mike Richman is a writer and editor in VA Research Communications. He joined VA in 2016 after working for 15 years at the Voice of America.

Read this article:
VA researchers study effects of smoking on therapeutic stem cells - VAntage Point Blog

Here’s Why Proposition 14, the $5.5 Billion Stem Cell Bond, is a Bad Idea – City Watch

LA WATCHDOG--Authorizes $5.5 billion state bonds for: stem cell and other medical research, including training; research facility construction; administrative costs.

Dedicates $1.5 billion to brain-related diseases. Appropriates General Fund moneys for repayment. Expands related programs. Fiscal Impact: Increased state costs to repay bonds estimated at about $260 million per year over the next roughly 30 years.[$7.8 billion including interest]

In 2004, Proposition 71 was approved by 59% of the voters. It established the California Institute for Regenerative Medicine to oversee stem cell research and provide funding for research and research facilities. It also amended the States Constitution to allow stem cell research. And importantly, it authorized the issuance of $3 billion in general obligation bonds to fund research, putting the State on the hook for the repayment of the bonds at an average cost of $200 million a year for 30 years. There was also the prospect of huge royalties from the commercialization of the research.

But times have changed and the need for the State and its taxpayers to spend $7.8 billion for stem cell research over the next thirty years is an expenditure we cannot afford in this age of deficits and Covid-19.

In 2004, the federal government refused to fund stem cell research because of religious objections. With the change in administrations in 2009, the federal government began to fund stem cell research, lessening, if not eliminating, the need for Californians to fund this research.

Today, there are also billions of venture capital and corporate dollars actively looking to invest in stem cell research, negating the proponents arguments that $5.5 billion is required to fund the CIRMs efforts and overhead for the next 15 years.

Furthermore, if the Legislature and Governor believe that the CIRM is a worthwhile organization, they could allocate resources to fund the operations and bureaucracy of the Institute while it looks for and identifies worthwhile investments that are funded by foundations and the private sector. This would save California over $7 billion over the next 30 years.

Another alternative would be for the CIRM to seek outside funding to fund its daily operations. Like with the State, this would also require the Institute to justify its existence and its ability to develop attractive investment opportunities.

Based on the 17,000 word (!) ballot measure, administrative costs are not to exceed to 7.5% of the $5.5 billion in bonds, or $412.5 million over the next 15 to 20 years. That implies an annual cost in the range of $20 to $30 million.

Another issue that has been raised is the lack of transparency and accountability of the CIRM, especially given the lack of legislative oversight and the many conflicts of interest on the part of many members of the governing board. These are not addressed in a meaningful way in the ballot measure.

As for royalties and the return on Californias investments, this windfall has not materialized. Since 2004, the State has received a measly $350,000, representing a return of one hundredth of 1% (0.01%).

In this time of budget deficits, the State and Californians cannot afford to spend $7.8 billion (including interest) over the next thirty years on investments which have no return, especially when there is third party money that will fund any worthwhile investment.

Save $7.8 billion and vote NO on Proposition 14.

(Jack Humphreville writes LA Watchdog for CityWatch. He is the President of the DWP Advocacy Committee and is the Budget and DWP representative for the Greater Wilshire Neighborhood Council. He is a Neighborhood Council Budget Advocate. He can be reached at: lajack@gmail.com.)

-cw

Read more here:
Here's Why Proposition 14, the $5.5 Billion Stem Cell Bond, is a Bad Idea - City Watch

STEM CELL UMBILICAL CORD BLOOD MARKET TRENDS, GROWTH, REGIONAL ANALYSIS, GROWTH REVENUE WITH TOP COMPANY’S AND FORECAST TO 2027 The Daily Chronicle -…

Stem Cell Umbilical Cord Blood research report provides deep insights into the Global Stem Cell Umbilical Cord Blood market revenue, parent market trends, macro-economic indicators, and governing factors, along with market attractiveness per market segment. The report provides an overview of the growth rate of the Stem Cell Umbilical Cord Blood during the forecast period, i.e., 20202027. Most importantly, the report further identifies the qualitative impact of various market factors on market segments and geographies. The research segments the market on the basis of product type, application, technology, and region. To offer more clarity regarding the industry, the report takes a closer look at the current status of various factors including but not limited to supply chain management, niche markets, distribution channel, trade, supply, and demand and production capability across different countries.

The Covid-19 (coronavirus) pandemic is impacting society and the overall economy across the world. The impact of this pandemic is growing day by day as well as affecting the supply chain. The COVID-19 crisis is creating uncertainty in the stock market, massive slowing of supply chain, falling business confidence, and increasing panic among the customer segments. The overall effect of the pandemic is impacting the production process of several industries including Biotechnology Industry, and many more. Trade barriers are further restraining the demand- supply outlook. As government of different regions have already announced total lockdown and temporarily shutdown of industries, the overall production process being adversely affected; thus, hinder the overall Stem Cell Umbilical Cord Blood market globally. This report on Stem Cell Umbilical Cord Blood market provides the analysis on impact on Covid-19 on various business segments and country markets. The report also showcase market trends and forecast to 2027, factoring the impact of Covid -19 Situation.

Get Sample PDF athttps://www.theinsightpartners.com/sample/TIPRE00005170/

Stem cells from umbilical cord blood is preserved as it has capabilities of regenerating into any type of body cells. In life threatening malignant and non-malignant diseases, hematopoietic stem cells transplantation (HSCT) can help in saving the life of person. In addition, the therapy is comparatively cost effective and has limited side effects. Umbilical stem cells are used for treating cancer, blood diseases like anemia and certain immune system disorders.

The stem cell umbilical cord blood (UCB) market is anticipated to grow in the forecast period owing to increasing occurrence of chronic diseases as well as rising support of government and private sector for research and development. In addition, the growing popularity for umbilical cord storage in developing countries is expected to create opportunities for market growth during the forecast period

Key players:

Detailed segmentation of the market, on the basis of Storagr Option, Disease, End User, Geography and a descriptive structure of trends of the segments and sub-segments are elaborated in the report. It also provides the market size and estimates a forecast from the year 2018 to 2027 with respect to five major regions, namely; North America, Europe, Asia-Pacific (APAC), Middle East and Africa (MEA) and South & Central America. The report also provides exhaustive PEST analysis for all five regions after evaluating political, economic, social and technological factors effecting the Stem Cell Umbilical Cord Blood market.

Key Reasons:

Buy Complete Report athttps://www.theinsightpartners.com/buy/TIPRE00005170/

About us: The Insight Partners is a one stop industry research provider of actionable intelligence. We help our clients in getting solutions to their research requirements through our syndicated and consulting research services. We are a specialist in Technology, Healthcare, Manufacturing, Automotive and Defense.

Contact us: Call: +1-646-491-9876 Email:[emailprotected]

Follow this link:
STEM CELL UMBILICAL CORD BLOOD MARKET TRENDS, GROWTH, REGIONAL ANALYSIS, GROWTH REVENUE WITH TOP COMPANY'S AND FORECAST TO 2027 The Daily Chronicle -...

Adipose Derived Stem Cell Therapy Market : Facts, Figures and Analytical Insights 2020-2025 – Good Night, Good Hockey

The Adipose Derived Stem Cell Therapy Market report is a compilation of first-hand information, qualitative and quantitative assessment by industry analysts, inputs from industry experts and industry participants across the value chain. The report provides an in-depth analysis of parent market trends, macro-economic indicators and governing factors along with market attractiveness as per segments. The report also maps the qualitative impact of various market factors on market segments and geographies. We analyzed the impact of COVID-19 (Corona Virus) on the product industry chain based on the upstream and downstream markets, on various regions and major countries and on the future development of the industry are pointed out.

Click the link to get a Sample Copy of the Report:

https://www.marketinsightsreports.com/reports/07022127977/global-adipose-derived-stem-cell-therapy-market-growth-status-and-outlook-2020-2025/inquiry?source=gnghockey&Mode=12

The 132 pages report presents the market competitive landscape and a corresponding detailed analysis of the major vendor/key players in the market. Top Companies in the Global Adipose Derived Stem Cell Therapy Market: AlloCure, Tissue Genesis, Antria, Cellleris, Corestem, Celgene Corporation, Mesoblast, Cytori Therapeutics, Pluristem Therapeutics, Intrexon, Lonza, BioRestorative Therapies, Pluristem Therapeutics, iXCells Biotechno and others.

Global Adipose Derived Stem Cell Therapy Market Split By Product Type And Applications:

This report segments the global Adipose Derived Stem Cell Therapy market on the basis of Types is:

Autologous Stem Cells

Allogeneic Stem Cells

On the basis of Application, the Global Adipose Derived Stem Cell Therapy market is segmented into:

Therapeutic Application

Research Application

The research study evaluates the overall size of the market, by making use of a bottom-up approach, wherein data for different industry verticals, and end-user industries and its applications across various product types have been recorded and predicted during the forecast period. These segments and sub-segments have been documented from the industry specialists and professionals, as well as company representatives, and are outwardly validated by analyzing previous years data of these segments and sub-segments for getting an accurate and complete market size.

Influence Of The Adipose Derived Stem Cell Therapy Market Report:

-Comprehensive assessment of all opportunities and risk in the Adipose Derived Stem Cell Therapy market.

Adipose Derived Stem Cell Therapy market recent innovations and major events.

-A Detailed study of business strategies for growth of the Adipose Derived Stem Cell Therapy market-leading players.

-Conclusive study about the growth plot of Adipose Derived Stem Cell Therapy market for forthcoming years.

-In-depth understanding of Adipose Derived Stem Cell Therapy market-particular drivers, constraints and major micro markets.

-Favorable impression inside vital technological and market latest trends striking the Adipose Derived Stem Cell Therapy market.

The report has 150 tables and figures browse the report description and TOC:

https://www.marketinsightsreports.com/reports/07022127977/global-adipose-derived-stem-cell-therapy-market-growth-status-and-outlook-2020-2025?source=gnghockey&Mode=12

What Are The Market Factors That Are Explained In The Report?

Key Strategic Developments:The study also includes the key strategic developments of the market, comprising R&D, new product launch, M&A, agreements, collaborations, partnerships, joint ventures, and regional growth of the leading competitors operating in the market on a global and regional scale.

Analytical Tools:The Global Adipose Derived Stem Cell Therapy Market Report includes the accurately studied and assessed data of the key industry players and their scope in the market by means of a number of analytical tools. The analytical tools such as Porters five forces analysis, SWOT analysis, feasibility study, and investment return analysis have been used to analyze the growth of the key players operating in the market.

Key Market Features:The report evaluated key market features, including revenue, price, capacity, capacity utilization rate, gross, production, production rate, consumption, import/export, supply/demand, cost, market share, CAGR, and gross margin. In addition, the study offers a comprehensive study of the key market dynamics and their latest trends, along with pertinent market segments and sub-segments.

Customization of the Report: This report can be customized as per your needs for additional data up to 3 companies or countries or 40 analyst hours.

If you have any questions about any of our Adipose Derived Stem Cell Therapy market report or would like to schedule a personalized free demo of Adipose Derived Stem Cell Therapy market report, please do not hesitate to contact me at irfan@marketinsightsreports.com

Best wishes,

Irfan Tamboli

Head of Sales Operations

Market Insights Reports

Tel: + 1704 266 3234 | +91-750-707-8687

Email: sales@marketinsightsreports.com | irfan@marketinsightsreports.com

About Us:

MarketInsightsReports provides syndicated market research on industry verticals including Healthcare, Information and Communication Technology (ICT), Technology and Media, Chemicals, Materials, Energy, Heavy Industry, etc. MarketInsightsReports provides global and regional market intelligence coverage, a 360-degree market view which includes statistical forecasts, competitive landscape, detailed segmentation, key trends, and strategic recommendations.

Continued here:
Adipose Derived Stem Cell Therapy Market : Facts, Figures and Analytical Insights 2020-2025 - Good Night, Good Hockey

Takeda opens cell therapy manufacturing facility tucked right in its Boston R&D hub – Endpoints News

When Takeda unveiled its translational cell therapy engine early last year, the Japanese pharma made it clear the crew, under Novartis vet Stefan Wildt, is going all the way: clinical expertise, bioengineering chops, world-class collaborations, plus chemistry, manufacturing and control.

The final piece of the puzzle has now fallen in place, with the opening of a 24,000 square-foot cell therapy manufacturing facility at its R&D headquarters in Boston.

In that early space, having it situated in proximity to our teams is quite powerful, Chris Arendt, head of the oncology therapeutic area unit, told Endpoints News. When you think about it, the process defines very much the medicine and the cell therapy space

Designed to produce clinical-grade material from discovery through pivotal Phase IIb trials, the site will support five ongoing pacts. They include pluripotent stem cell work with Kyoto University Nobel laureate Shinya Yamanaka, gamma delta T cell research with Adrian Hayday and his biotech, armored CAR-Ts with Koji Tamada at Noile-Immune Biotech, next-gen CARs with Memorial Sloan Ketterings Michel Sadelain, and finally CAR-NK with Katy Rezvani at MD Anderson.

With three programs now in the clinic, Takeda is now picking two more to test in humans in 2021, Arendt said. While each research partnership has taken on its own bespoke approach to manufacturing up to now, the new facility will provide a central spot to lock down the process development as close to the final product as possible.

At the forefront are TAK-007, an allogeneic CD19-targeted CAR-NK being tested in Phase I/II for relapsed or refractory non-Hodgkins lymphoma; TAK-940, 19(T2)28z1xx CAR-T cells featuring a next-gen signaling domain from MSK; and TAK-102, a cytokine and chemokine armored CAR-T directed at GPC3-expressing previously treated solid tumors. The latter two are in first-in-human trials.

Having a dedicated facility scales the operations up so that the team can simultaneously advance multiple programs, he added.

Before the Covid-19 pandemic sucked out all the oxygen in the room, the booming cell therapy markets demand for physical infrastructure captured considerable attention. Gileads Kite constructed its own viral vector manufacturing center in order to leave no stone unturned. Contract manufacturers like Catalent were snapping up space, and even Deerfield got into the game with a splashy, $1.1 billion entrance.

The way hes built the team now grown to well over 150 scientists the learnings from any one program can be quickly applied to the whole portfolio, Wildt noted.

We wanted to place the engine team at that sweet spot between late-stage discovery and rapidly putting forward innovative ideas and concepts into clinical translation, he said. It was just a concept a few years ago. And now we can partner with hospitals and patients and really see hopefully we can be successful on their behalf.

See original here:
Takeda opens cell therapy manufacturing facility tucked right in its Boston R&D hub - Endpoints News

Stem cells, like Rosh Hashanah, give the opportunity to be reborn – The Jerusalem Post

Rosh Hashanah is the day of pregnancy of the world. Hayom Harat Olam (The day of creation of the world). What does it mean? Medical research today is focusing on a fascinating and visionary field, which is the study of "stem cells." The uniqueness of stem cells comes from two main features which distinguish them from other cells. The first is that they are still 'neutral cells', meaning, they have not yet received their final identity and purpose in the body, so they have not yet finalized their differentiation process. As a result of this, they are able to differentiate and can develop into one of many types of mature cells, such as a skin cell, a muscle cell or a blood cell. By doing so, new cells are created, which can regenerate various tissues and organs. The second unique feature of stem cells is that they are able to divide and multiply infinitely and produce identical cells. Thus, a constant pool of unsorted stem cells that have not acquired a final designation is preserved. The possibilities of healing, cell regeneration and the human body in general are fascinating, and the field of stem cells is one of the leading fields in the world. Its healing potentials are so vast, not only when it comes to repairing the damaged, but also recreating something more true and precise. When I think of Rosh Hashanah from a spiritual standpoint, it feels like today is the birth of the world. We have before us 353 days (because some Jewish months arent full) which have not yet been defined by how they will play out and how they will look. It is unknown how we will succeed as individuals, and how we will succeed as nation. Interestingly, the second feature that exists with stem cells also connects to Rosh Hashanah. On this holy day, we are praying and asking Hashem from a place of "anything is possible" there are no boundaries, no glass barriers, no one is stopping us from simply praying and asking. cnxps.cmd.push(function () { cnxps({ playerId: '36af7c51-0caf-4741-9824-2c941fc6c17b' }).render('4c4d856e0e6f4e3d808bbc1715e132f6'); }); Hashem, everything is completely in our hands! We can change the world and create something entirely new. Rosh Hashanah gives us the opportunity to create and build anew; its the source of rebirth for the relationship between man and his friend, man and Hashem, and of course, man as one who is part of a nation and of the entire world. It's not for nothing that it is written in the Talmud Yerushalmi that whoever spends his time on Rosh Hashanah sleeping, his luck will also sleep. It's the time to act, ask, beg and change. The cells will divide, the decisions made will be in place, and the abundance from shamayim (heaven) will come down. We now have a very great ability and opportunity to influence that. Please dont miss out on this opportunity! Be that as it may, today is Harat Olam the pregnancy of the world. It is our responsibility to pray that this pregnancy will be the best it can be. Have a happy and sweet New Year. Rabbi Yitzak Neriya is the head of the Torah Betzion yeshiva and founder of the Echad Lechad (One to One) foundation.

See original here:
Stem cells, like Rosh Hashanah, give the opportunity to be reborn - The Jerusalem Post

Pet laser pointers have enough power to blast away cells in the back of the eye – The Ohio State University News

Laser pointers used to exercise pets may seem like safe and simple low-powered devices, but an Ohio teen learned the hard way that staring at the narrow beam can cause permanent eye damage.

His minimal vision loss tells some of the story, but a high-resolution optical imaging device developed by Ohio State University researchers showed in stark detail that cells in the boys retinas are missing blasted away by the laser, his ophthalmologist explained.

This area of the eye is home to photoreceptors, light-sensitive cells (often referred to as rods and cones) that allow us to see. These cells are most dense in the center of the retina and give us the perception of vision and color.

Theres just nothing left there, said Frederick Davidorf, professor of ophthalmology and visual science at Ohio State and co-author of a paper describing the case. The affected areas are devoid of cones.

Only with the optical scanning system, engineered by Nathan Doble, associate professor of optometry at Ohio State, could scientists count individual cells to see precisely what had happened to the teens eyes. Both eyes were damaged, the right more extensively.

The case study is published online in the journal Retinal Cases & Brief Reports and will appear in a future print issue.

The case serves as a cautionary tale about the risk of staring at laser pointers, which both Doble and Davidorf noted often pack much more power than advertised.

It is also the first published report of laser eye damage captured by this specific imaging system, showing how valuable this research equipment can be in understanding the exact extent of damage caused by the laser.

The imaging system can be thought as a powerful microscope that can magnify the view of retinal cells that are equal in size to about 1/20th the width of a human hair. One of the main research goals in Dobles lab is to utilize such high-resolution imaging systems to detect and monitor various eye diseases such as age-related macular degeneration, diabetic retinopathy and glaucoma.

It has been described as looking at the retina through a straw, said Doble, a lead author of the paper. We can see much more detail than you would see with standard clinical imaging. We do not image large areas of the retina, but the areas we do image are at a much higher level of resolution.

The 14-year-old boy, not identified in the article, and a friend were playing with pet laser pointers when he stared directly at the laser for several seconds. He described the initial effect as a bright light that limited his vision for several minutes.

By the time he saw Davidorf five months later, the patient said that if he were looking at text with only his right eye, a single letter would be missing, but with both eyes he could not detect any problems. Though he otherwise had 20/25 and 20/20 vision, a standard clinical exam showed lesions in both eyes that were diagnosed as macular laser burns.

The damage came into clearer view when Doble imaged the retinas with his device, called an adaptive optics-optical coherence tomography-scanning laser ophthalmoscope: The two lesions in the right eye and one in the left eye appear as black gaps in a sea of individual cells.

The scope is equipped with a specialized mirror that has been deformed almost like a funhouse mirror, Doble said, correcting for the slightest motions even motion related to the patients heartbeat as the researchers shine light into the eye.

The mirror allows us to bypass the optics of the aberrations or distortions in your eye and gives us the really sharp image of the back of the eye, Doble said. Each individual image covers only a small field of view, so the researchers stitch images together to see the entire target area of concern.

The high-resolution images are similar to what scientists can see when they view a slice of tissue under a microscope only in this case, the tissue doesnt have to be biopsied to be seen up close.

Doble, also an associate professor of ophthalmology and visual science, doesnt intend to market the scope or make it widely available it is one of only five known custom-built devices of its kind in the United States. As an optical engineer, his emphasis is producing images that can help increase understanding of eye diseases as they progress.

Most recently, his lab published images of retinal cells called ganglion cells from patients with glaucoma, a disease that damages the optic nerve.

The ganglion cells are some of the first cells affected by glaucoma, so potentially counting these cells might be a very sensitive measure for this condition, Doble said. We can also follow the same patient over time so the potential of new stem-cell or genetic therapies can be evaluated objectively by counting the number of individual cells as the disease progresses.

In this case study, the researchers scanned the teens eyes twice, 11 and 20 months after the injury, and found slight decreases in the size of the lesions over that time period.

But its never going to fully heal, Davidorf said. There will always be scarring there.

Other Ohio State co-authors of the study include Carol Vitellas, Elaine Wells-Gray, Nayanika Challa and Stacey S. Choi.

View original post here:
Pet laser pointers have enough power to blast away cells in the back of the eye - The Ohio State University News

Artificial blood edges closer to reality, spurred by pandemic-driven shortage – Genetic Literacy Project

While scientists have developed backups for most parts of our bodiesfrom prosthetic limbs to titanium teeth implantsthe production of artificial blood has eluded them. Now, helped by advances in stem-cell research and interest from investors, scientists are closer than ever to coming up with a blood substitute.

Blood made in a lab could add to thesupply from human donors, which can drop dangerously low during natural disasters or pandemics, as the U.S. saw in March. It would also provide a lifesaving remedy for those with blood disorders that prevent them from accepting donations. And it could be quality-controlled for viruses and pathogens in a way that researchers say human samples cant be.

Related article: Can artificial intelligence improve IVF success rates?

Low-income countries have less than one-fifth the number of donors of high-income countries, according to the World Health Organization.

Some religious groups, including the Jehovahs Witnesses, dont accept transfusions of donated blood as part of their faith. A representative says blood substitutes may be helpful.

Researchers and companies believe that blood made from induced pluripotent stem cells, or IPS cells, could solve some of these problems by allowing them to manufacture pathogen-free blood that would be accepted by nearly all patients.

Dr. [Koji] Etos study, which began in March 2019 and ends in early 2021, is one of a number slated to take place over the next year.

Read the original post

Read more here:
Artificial blood edges closer to reality, spurred by pandemic-driven shortage - Genetic Literacy Project

Stem Cell Market Expected to Witness the Highest Growth 2028 – The Daily Chronicle

Market Scenario of the Stem Cell Market:

The most recent Stem Cell Market Research study includes some significant activities of the current market size for the worldwide Stem Cell market. It presents a point by point analysis dependent on the exhaustive research of the market elements like market size, development situation, potential opportunities, and operation landscape and trend analysis. This report centers around the Stem Cell-business status, presents volume and worth, key market, product type, consumers, regions, and key players.

Sample Copy of This Report @ https://www.quincemarketinsights.com/request-sample-40210?utm_source=TDC/komal

The prominent players covered in this report: Thermo Fisher Scientific, Qiagen NV, Sigma Aldrich, Becton, Dickinson and Company, and Stem Cell Technologies

The market is segmented into By Source (Adult Stem Cell, Human Embryonic Cell, Pluripotent Stem Cell, and Others), By Application (Therapeutic and Drug Development and Discovery), By Treatment Type (Allogeneic, Autologous, and Syngeneic), By Stem Cell Banking (Service & Technology and Banking Type).

Geographical segments are North America, Europe, Asia Pacific, Middle East & Africa, and South America.

A 360 degree outline of the competitive scenario of the Global Stem Cell Market is presented by Quince Market Insights. It has a massive data allied to the recent product and technological developments in the markets.

It has a wide-ranging analysis of the impact of these advancements on the markets future growth, wide-ranging analysis of these extensions on the markets future growth. The research report studies the market in a detailed manner by explaining the key facets of the market that are foreseeable to have a countable stimulus on its developing extrapolations over the forecast period.

Get ToC for the overview of the premium report @ https://www.quincemarketinsights.com/request-toc-40210?utm_source=TDC/komal

This is anticipated to drive the Global Stem Cell Market over the forecast period. This research report covers the market landscape and its progress prospects in the near future. After studying key companies, the report focuses on the new entrants contributing to the growth of the market. Most companies in the Global Stem Cell Market are currently adopting new technological trends in the market.

Finally, the researchers throw light on different ways to discover the strengths, weaknesses, opportunities, and threats affecting the growth of the Global Stem Cell Market. The feasibility of the new report is also measured in this research report.

Reasons for buying this report:

Make an Enquiry for purchasing this Report @ https://www.quincemarketinsights.com/enquiry-before-buying/enquiry-before-buying-40210?utm_source=TDC/komal

About Us:

QMI has the most comprehensive collection of market research products and services available on the web. We deliver reports from virtually all major publications and refresh our list regularly to provide you with immediate online access to the worlds most extensive and up-to-date archive of professional insights into global markets, companies, goods, and patterns.

Contact Us:

Quince Market Insights

Ajay D. (Knowledge Partner)

Office No- A109

Pune, Maharashtra 411028

Phone: APAC +91 706 672 4848 / US +1 208 405 2835 / UK +44 1444 39 0986

Email: [emailprotected]

Web: https://www.quincemarketinsights.com

Link:
Stem Cell Market Expected to Witness the Highest Growth 2028 - The Daily Chronicle